These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10605477)

  • 21. Antimicrobial susceptibility of Propionibacterium acnes isolates from acne patients in Colombia.
    Mendoza N; Hernandez PO; Tyring SK; Haitz KA; Motta A
    Int J Dermatol; 2013 Jun; 52(6):688-92. PubMed ID: 23451873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility of strains of Propionibacterium acnes isolated from inflammatory acne.
    Gübelin W; Martínez MA; Molina MT; Zapata S; Valenzuela ME
    Rev Latinoam Microbiol; 2006; 48(1):14-6. PubMed ID: 17357569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Propionibacterium: resistance of acne to antibiotics.
    Oakley A; Rademaker M; Duffill M; Leng R; Shewan J
    N Z Med J; 1995 Feb; 108(993):43-4. PubMed ID: 7891939
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan.
    Nakase K; Nakaminami H; Takenaka Y; Hayashi N; Kawashima M; Noguchi N
    J Med Microbiol; 2014 May; 63(Pt 5):721-728. PubMed ID: 24523159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propionibacterium acnes is a causative agent in periprosthetic infections - important implications for the treatment of acne vulgaris.
    Otto-Lambertz C; Jung N; Sunderkötter C
    J Dtsch Dermatol Ges; 2019 Apr; 17(4):454-455. PubMed ID: 30873723
    [No Abstract]   [Full Text] [Related]  

  • 26. Current management of acne.
    O'Loughlin S
    Ir Med J; 1997; 90(3):92-3. PubMed ID: 9183086
    [No Abstract]   [Full Text] [Related]  

  • 27. Susceptibility of Propionibacterium acnes and Staphylococcus epidermidis to killing by MPO-halide system products. Implication for taurine bromamine as a new candidate for topical therapy in treating acne vulgaris.
    Marcinkiewicz J; Biedroń R; Białecka A; Kasprowicz A; Mak M; Targosz M
    Arch Immunol Ther Exp (Warsz); 2006; 54(1):61-8. PubMed ID: 16642259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial resistance in French acne patients.
    Dumont-Wallon G; Moyse D; Blouin E; Dréno B
    Int J Dermatol; 2010 Mar; 49(3):283-8. PubMed ID: 20465665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant propionibacteria in patients with acne.
    Coates P; Vyakrnam S; Ravenscroft JC; Stables GI; Cunliffe WJ; Leyden JJ; Johnson J; Eady EA; Cove JH
    Br J Dermatol; 2005 Dec; 153(6):1126-36. PubMed ID: 16307647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base.
    Kurokawa I; Akamatsu H; Nishijima S; Asada Y; Kawabata S
    J Am Acad Dermatol; 1991 Oct; 25(4):674-81. PubMed ID: 1838749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effectiveness of once-daily levofloxacin for inflammatory acne with high concentrations in the lesions.
    Kawada A; Wada T; Oiso N
    J Dermatol; 2012 Jan; 39(1):94-6. PubMed ID: 21545499
    [No Abstract]   [Full Text] [Related]  

  • 32. Relationship between quinolone use and resistance of Staphylococcus epidermidis in patients with acne vulgaris.
    Nakase K; Yoshida A; Saita H; Hayashi N; Nishijima S; Nakaminami H; Noguchi N
    J Dermatol; 2019 Sep; 46(9):782-786. PubMed ID: 31254314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibilities of Propionibacterium acnes isolated from patients with acne vulgaris.
    Ishida N; Nakaminami H; Noguchi N; Kurokawa I; Nishijima S; Sasatsu M
    Microbiol Immunol; 2008 Dec; 52(12):621-4. PubMed ID: 19120976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic possibilities for acne vulgaris].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 1998 May; 21(5):154-6. PubMed ID: 9617104
    [No Abstract]   [Full Text] [Related]  

  • 35. The antimicrobial activities of Psidium guajava and Juglans regia leaf extracts to acne-developing organisms.
    Qadan F; Thewaini AJ; Ali DA; Afifi R; Elkhawad A; Matalka KZ
    Am J Chin Med; 2005; 33(2):197-204. PubMed ID: 15974479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Propionibacterium acnes Has Low Susceptibility to Chlorhexidine Digluconate.
    Nakase K; Fukushima H; Yukawa T; Nakaminami H; Fujii T; Noguchi N
    Surg Infect (Larchmt); 2018 Apr; 19(3):298-302. PubMed ID: 29447075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotic resistance in the topical treatment of acne vulgaris.
    Leyden JJ
    Cutis; 2004 Jun; 73(6 Suppl):6-10. PubMed ID: 15228128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes.
    Yoon JY; Kwon HH; Min SU; Thiboutot DM; Suh DH
    J Invest Dermatol; 2013 Feb; 133(2):429-40. PubMed ID: 23096708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: a status report.
    Leyden JJ; Del Rosso JQ; Webster GF
    Dermatol Clin; 2009 Jan; 27(1):1-15. PubMed ID: 18984363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Human beta defensins: a new perspective in acne treatment?].
    Körber A; Lehnen M; Grabbe S; Dissemond J
    Dtsch Med Wochenschr; 2005 Feb; 130(5):210-2. PubMed ID: 15678389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.